Results 121 to 130 of about 177,994 (348)

Supplementary Figure 6 from Perturbation of Rb, p53, and Brca1 or Brca2 Cooperate in Inducing Metastatic Serous Epithelial Ovarian Cancer [PDF]

, 2023
Ludmila Szabova, Chaoying Yin, Sujata Bupp, Theresa M. Guerin, Jerome Schlomer, Deborah B. Householder, Maureen Baran, Ming Yi, Yurong Song, Wenping Sun, Jonathan E. McDunn, Philip Martin, Terry Van Dyke, Simone Difilippantonio   +13 more
openalex   +1 more source

Tumor Infiltrating Lymphocyte Therapy Combined With PD‐1/LAG‐3 Inhibition in Patients With Recurrent Platinum‐Resistant Ovarian Cancer

International Journal of Cancer, EarlyView.
The detection of tumor‐infiltrating lymphocytes (TILs) is a positive prognostic factor in ovarian cancer. Moreover, TILs are significantly boosted by immunotherapy, though ovarian cancer patients have seen limited benefit from immune therapies. This study investigated the safety and feasibility of TIL therapy combined with PD‐1 and LAG‐3 inhibitors in ...
Tine J. Monberg, Cathrine L. Lorentzen, Marie C. W. Westergaard, Trine Z. Iversen, Troels H. Borch, Marco Donia, Sigrid M. Mannering, Stine E. W. Banke, Özcan Met, Inge Marie Svane   +9 more
wiley   +1 more source

Genetic screening of FFPE breast cancer biopsies for the BRCA1-185delAG mutation in Trinidad and Tobago

Revista Panamericana de Salud Pública
Objective. To investigate whether the quality and quantity of genomic DNA harnessed from existing formalin-fixed paraffin-embedded (FFPE) breast cancer biopsy tissue samples in the public health system of Trinidad and Tobago (T&T) were sufficient for ...
Sheherazade Crystal Abrahim, Dulari Bansraj, Royanne Edwards, Reinand Thompson, Roma Rambaran, Allana Roach, Wayne A. Warner, A. V. Chalapathi Rao, Chandrashekar Unakal, Rajini Rani Haraksingh   +9 more
doaj   +1 more source

Breast cancer therapy for BRCA1 carriers: moving towards platinum standard? [PDF]

, 2009
Evgeny N. Imyanitov
openalex   +1 more source

PALB2 chromatin recruitment restores homologous recombination in BRCA1-deficient cells depleted of 53BP1 [PDF]

, 2020
Rimma Belotserkovskaya, Elisenda Raga Gil, Nicola Lawrence, Richard Butler, Gillian Clifford, Marcus D. Wilson, Stephen P. Jackson   +6 more
openalex   +1 more source

Supplementary Figure 4 from Targeting BRCA1 Localization to Augment Breast Tumor Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition [PDF]

, 2023
Eddy S. Yang, Somaira Nowsheen, Mohammad Azizur Rahman, Rebecca S. Cook, Fen Xia   +4 more
openalex   +1 more source

Ovarian Cancer: Epidemiology, Disease Mechanisms, New Diagnosis and Treatment Strategies, and Research Directions

iNew Medicine, EarlyView.
ABSTRACT Ovarian cancer (OC) continues to be the deadliest gynecological malignancy and a significant cause of cancer‐related mortality among women worldwide. Standard treatment strategies typically entail platinum‐based chemotherapy in conjunction with cytoreductive surgery.
Zunera Khalid, Weirong Fan, Farah Nazir, Yixiang Xing, Tengchuan Jin   +4 more
wiley   +1 more source

A novel rapid and sensitive BRCA1/2 mutation detection method based on pooled DGGE and targeted sequencing [PDF]

, 2007
P. J. van Diest, Gerard Pals
openalex   +1 more source

SUMOylation regulates tumorigenesis and progression: Molecular mechanisms and therapeutic applications

Interdisciplinary Medicine, EarlyView.
SUMOylation, a dynamic post‐translational modification, acts as a master regulator at the heart of tumor malignancy. Our work delineates how the SUMOylation cycle—mediated by E1/E2/E3 enzymes and reversed by SENPs—orchestrates multiple hallmarks of cancer. The central pathway converges on three critical pathological axes: 1.
Yimao Wu, Zichang Chen, Yinting Hu, Gokhan Zengin, Qian Zhang, Meng‐Yao Li, Wenlong Sun   +6 more
wiley   +1 more source

Role of the Nrf2/ARE Pathway in the mtDNA Reparation

Frontiers in Bioscience-Landmark
Mitochondrial DNA (mtDNA) is located in the mitochondrial matrix, in close proximity to major sources of reactive oxygen species (ROS) in the cell. This makes mtDNA one of the most susceptible components to damage in the cell.
Artem P. Gureev, Ekaterina V. Chernyshova, Ekaterina P. Krutskikh, Irina S. Sadovnikova, Elena E. Tekutskaya, Anna A. Dorohova   +5 more
doaj   +1 more source